Clinical implications and outcomes of the ORION Phase III trials

作者：Brandts J, Ray KK · 发表于：Future cardiology · 年份：2021 · DOI：10.2217/fca-2020-0150 · 研究领域：LDL-cholesterol、PCSK9、atherosclerosis、cardiovascular disease、inclisiran、siRNA

Inclisiran is a siRNA inhibiting hepatic PCSK9 synthesis. As a first-in-class therapy, inclisiran has been assessed within the ORION trial program for its low-density lipoprotein cholesterol (LDL-C) lowering efficacy and clinical safety. Phase II and III trials have shown that inclisiran lowers LDL-C by about 50% with an infrequent dosing schedule in patients with established atherosclerotic cardiovascular disease and those at high risk, including patients with heterozygous familial hypercholesterolemia. Ongoing Phase III trials will provide evidence on longer-term safety and effectiveness, and inclisiran's efficacy in patients with homozygous familial hypercholesterolemia. Furthermore, the ORION-4 trial will assess inclisiran's impact on cardiovascular outcomes.